Literature DB >> 30411406

Apolipoprotein A-Ib as a biomarker of focal segmental glomerulosclerosis recurrence after kidney transplantation: diagnostic performance and assessment of its prognostic value - a multi-centre cohort study.

Natàlia Puig-Gay1, Conxita Jacobs-Cacha1,2, Joana Sellarès2, Lluís Guirado3, Francisco González Roncero4, Carlos Jiménez5, Sofía Zárraga6, Javier Paul7, Ricardo Lauzurica8, Ángel Alonso9, Ana Fernández10, Isabel Beneyto11, Auxiliadora Mazuecos12, Domingo Hernández13, Alberto Rodriguez-Benot14, Antonio Franco15, Luisa Jimeno16, Marta Crespo17, Anna Meseguer1, Francesc Moreso2, Daniel Seron2, Joan Lopez-Hellin1, Carmen Cantarell2.   

Abstract

Recurrence of idiopathic focal segmental glomerulosclerosis (FSGS) is a serious complication after kidney transplantation. FSGS relapse is suspected by a sudden increase in proteinuria but there is not an accurate noninvasive diagnostic tool to confirm this entity or to detect patients at risk. We aimed to validate the diagnostic performance of ApoA-Ib to detect FSGS relapses by measuring urinary ApoA-Ib in a retrospective cohort of 61 kidney transplanted patients (37 FSGS and 24 non-FSGS). In addition, to assess the ApoA-Ib predictive ability, ApoA-Ib was measured periodically in a prospective cohort of 13 idiopathic FSGS patients who were followed during 1 year after transplantation. ApoA-Ib had a sensitivity of 93.3% and a specificity of 90.9% to diagnose FSGS relapses, with a high negative predictive value (95.2%), confirming our previous results. In the prospective cohort, ApoA-Ib predated the recurrence in four of five episodes observed. In the nonrelapsing group (n = 9), ApoA-Ib was negative in 37 of 38 samples. ApoA-Ib has the potential to be a good diagnostic biomarker of FSGS relapses, providing a confident criterion to exclude false positives even in the presence of high proteinuria. It has also the potential to detect patients at risk of relapse, even before transplantation.
© 2018 Steunstichting ESOT.

Entities:  

Keywords:  apolipoprotein A-I; focal segmental glomerulosclerosis; kidney transplantation; recurrence

Mesh:

Substances:

Year:  2018        PMID: 30411406     DOI: 10.1111/tri.13372

Source DB:  PubMed          Journal:  Transpl Int        ISSN: 0934-0874            Impact factor:   3.782


  10 in total

1.  Should high molecular weight forms of apolipoprotein A-I be analyzed in urine of relapsing FSGS patients?

Authors:  Conxita Jacobs-Cachá; Joan López-Hellín
Journal:  Pediatr Nephrol       Date:  2019-07-24       Impact factor: 3.714

2.  Urinary apoAl: novel marker of renal disease?

Authors:  Amanda J Clark; Haichun Yang; Valentina Kon
Journal:  Pediatr Nephrol       Date:  2019-08-11       Impact factor: 3.714

3.  Urinary Protein Biomarker Panel for the Diagnosis of Antibody-Mediated Rejection in Kidney Transplant Recipients.

Authors:  Inge Mertens; Hanny Willems; Elisabet Van Loon; Karin Schildermans; Kurt Boonen; Geert Baggerman; Dirk Valkenborg; Wilfried Gwinner; Dany Anglicheau; Marie Essig; Pierre Marquet; Maarten Naesens
Journal:  Kidney Int Rep       Date:  2020-06-29

Review 4.  Recurrent and de novo Glomerulonephritis After Kidney Transplantation.

Authors:  Wai H Lim; Meena Shingde; Germaine Wong
Journal:  Front Immunol       Date:  2019-08-14       Impact factor: 7.561

5.  A misprocessed form of Apolipoprotein A-I is specifically associated with recurrent Focal Segmental Glomerulosclerosis.

Authors:  Conxita Jacobs-Cachá; Natàlia Puig-Gay; Dominic Helm; Mandy Rettel; Joana Sellarès; Anna Meseguer; Mikhail M Savitski; Francesc J Moreso; Maria José Soler; Daniel Seron; Joan Lopez-Hellin
Journal:  Sci Rep       Date:  2020-01-24       Impact factor: 4.379

6.  Relieving lipid accumulation through UCP1 suppresses the progression of acute kidney injury by promoting the AMPK/ULK1/autophagy pathway.

Authors:  Wei Xiong; Zhiyong Xiong; Anni Song; Chuntao Lei; Chen Ye; Chun Zhang
Journal:  Theranostics       Date:  2021-03-04       Impact factor: 11.556

7.  Integrated genomic, transcriptomic and metabolomic analysis reveals MDH2 mutation-induced metabolic disorder in recurrent focal segmental glomerulosclerosis.

Authors:  Qixia Shen; Lisha Teng; Yucheng Wang; Luying Guo; Feng Xu; Hongfeng Huang; Wenqing Xie; Qin Zhou; Ying Chen; Junwen Wang; Youying Mao; Jianghua Chen; Hong Jiang
Journal:  Front Immunol       Date:  2022-09-08       Impact factor: 8.786

Review 8.  Molecular stratification of idiopathic nephrotic syndrome.

Authors:  Moin A Saleem
Journal:  Nat Rev Nephrol       Date:  2019-10-25       Impact factor: 28.314

Review 9.  Challenges in primary focal segmental glomerulosclerosis diagnosis: from the diagnostic algorithm to novel biomarkers.

Authors:  Conxita Jacobs-Cachá; Ander Vergara; Clara García-Carro; Irene Agraz; Nestor Toapanta-Gaibor; Gema Ariceta; Francesc Moreso; Daniel Serón; Joan López-Hellín; Maria José Soler
Journal:  Clin Kidney J       Date:  2020-08-11

10.  A Specific Tubular ApoA-I Distribution Is Associated to FSGS Recurrence after Kidney Transplantation.

Authors:  Conxita Jacobs-Cachá; Natàlia Puig-Gay; Ander Vergara; Maria-Alejandra Gabaldon; Joana Sellarés; Yolanda Villena-Ortiz; Irene Agraz; Francesc Moreso; Maria José Soler; Daniel Serón; Joan López-Hellín
Journal:  J Clin Med       Date:  2021-05-18       Impact factor: 4.241

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.